1 completed, 1 unknown. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Optimized background therapy (OBT): new trials by email Literature Review of Optimized background therapy (OBT) trials Research Report on Optimized background therapy (OBT)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients UB-421, Optimized background therapy (OBT) - HIV-1 Infection | Phase 2 | Unknown | United BioPharma | 10 | 2023-12-01 | 2023-04-24 |
| Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects Optimized Background Therapy (OBT), maraviroc (UK-427,857) - HIV Infections | Phase 2 / Phase 3 | Completed | ViiV Healthcare | 190 | 2004-11-01 | 2010-12-07 |
HIV Infections (1)
United BioPharma (1) · ViiV Healthcare (1)
Australia (1) · Belgium (1) · Canada (1) · Germany (1) · Netherlands (1) · Spain (1) · Switzerland (1) · United Kingdom (1) · United States (1)